Compounds > 5'-hydroxypiroxicam
Page last updated: 2024-11-13

5'-hydroxypiroxicam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5'-hydroxypiroxicam: metabolite of pyroxicam; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54676301
CHEMBL ID1217
CHEBI ID175413
MeSH IDM0145414

Synonyms (23)

Synonym
unii-xbg963w8bl
xbg963w8bl ,
5-hydroxypiroxicam
2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide
CHEBI:175413
4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide
77459-78-0
5'-hydroxypiroxicam
hydroxy piroxicam metabolite
CHEMBL1217
DTXSID50228171
4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-1,1-dioxo-2h-1$l^{6},2-benzothiazine-3-carboxamide
5'-hydroxypiroxicam, vetranal(tm), analytical standard
76066-11-0
5 inverted exclamation mark -hydroxypiroxicam
E72292
2h-1,2-benzothiazine-3-carboxamide,4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide
piroxicam-5'-hydroxy
2h-1,2-benzothiazine-3-carboxamide, 4-hydroxy-n-(5-hydroxy-2-pyridinyl)-2-methyl-, 1,1-dioxide; 5'-hydroxypiroxicam
5'-hydroxy-piroxicam
piroxicam-5'-hydroxy 100 microg/ml in acetonitrile
WS-03101
4-hydroxy-n-(5-hydroxypyridin-2-yl)-2-methyl-2h-benzo[e][1,2]thiazine-3-carboxamide1,1-dioxide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect."( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation.
Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992)		0.28

Dosage Studied

ExcerptRelevanceReference
" Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study."( A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation.
Brater, DC; Figueroa, N; Greene, P; Mueller, BA; Rex, DK, 1992)		0.28
" creatinine clearance 88 +/- 13 ml min-1), and (3) elderly patients with renal insufficiency (creatinine clearance 60 +/- 10 ml min-1) following the administration of piroxicam 20 mg as a single dose and after chronic dosing of 20 mg once daily for 4 weeks."( The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
Brater, DC; Figueroa, NL; Hall, SD; Rudy, AC, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzothiazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID183497Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
AID183500Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Synthesis and antiinflammatory activity of metabolites of piroxicam.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's6 (50.00)18.2507
2000's0 (0.00)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9610pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
saccharin
Saccharin: Flavoring agent and non-nutritive sweetener.. saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.		1.96101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		2.4320methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
piroxicam
[no description available]		5.24121benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
mobiflex
tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.		1.9710heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
isoxicam
isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.		1.9710benzothiazine;
isoxazoles;
monocarboxylic acid amide		antirheumatic drug;
non-steroidal anti-inflammatory drug
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		01.9610
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		01.9610
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		01.9810
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9810
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		01.9810
Gastric Diseases
[description not available]		03.3611